Arcutis Biotherapeutics (ARQT)

Generated: August 8, 2026

Red Dot

Statistics

Metric	Value
Last Close	$25.29
Blended Price Target	25.97
Blended Margin of Safety	2.7% Fairly Valued
Rule of 40 (Next)	41.1%
Rule of 40 (Current)	44.7%
FCF-ROIC	11.7%
Sales Growth Next Year	29.4%
Sales Growth Current Year	33.0%
Sales 3-Year Avg	241.1%
Industry	Biotechnology

Analysis

Arcutis Biotherapeutics now looks like a promising but concentrated dermatology business rather than a diversified biopharma platform. Its growth outlook is real because ZORYVE is still early in its life cycle, but the durability of that growth depends heavily on how long one franchise can keep expanding across new dermatology indications and age groups. The business is therefore more resilient than a one-product launch story would suggest, but still far from stable or broad-based.^[1]^[11]^[15]

Revenue quality is improving, yet it remains fundamentally transactional and product-driven rather than recurring in the software or services sense. That means predictability comes from prescription persistence, payer access, and execution in a large but competitive market, not from contractual lock-in. The moat is real but narrow: it rests on clinical differentiation, dermatology specialization, and patent-protected intellectual property, while leadership appears capable and operationally focused, but not yet proven across multiple assets or cycles.^[1]^[11]^[15]

What the Company Does

Arcutis develops and sells prescription medicines for skin diseases, with its business centered on ZORYVE, a topical roflumilast product family used in dermatology. It makes money by selling these products through the pharmaceutical distribution and reimbursement system, so revenue is generated when patients fill prescriptions rather than through subscriptions or long-term contracts.^[1]^[11]

The current mix is overwhelmingly concentrated in ZORYVE, with multiple formulations and indications doing the heavy lifting. Publicly available recent sources indicate the company is still essentially a single-franchise commercial story, and a current breakdown by segment is not clearly disclosed in the materials reviewed.^[1]^[11]^[15]

Revenue Recurrence & Predictability

Arcutis does not have subscription revenue. Its revenue is best described as transactional and somewhat predictable only to the extent that repeat prescriptions, chronic-use indications, and payer coverage continue to support refill behavior over time.^[1]^[11]

That makes revenue more recurring than a one-time product launch, but less predictable than a contractual business. The company’s current momentum suggests a growing base of repeat use, yet each quarter still depends on prescription growth, access, and competitive selling conditions rather than automatic renewal economics.^[1]^[15]

Revenue Growth Durability

Arcutis can likely sustain above-market growth for a period because ZORYVE is still expanding into additional dermatology uses and patient populations. Recent company materials point to continued momentum from broader indication coverage and new access opportunities, which gives the franchise room to grow beyond its original launch base.^[11]^[15]

The main constraint is TAM penetration: the company must keep converting awareness into prescriptions in crowded dermatology categories. Growth should benefit from label expansion and sales-force execution, but it faces structural headwinds from reimbursement friction, entrenched competitors, and the normal slowdown that comes as an initial launch matures.^[1]^[11]^[15]

Economic Moat

Arcutis’s moat is built on intangible assets rather than network effects or switching costs. The relevant protections are product differentiation, dermatology expertise, and patent coverage extending into the 2030s, all of which help support ZORYVE’s position in a large treatment market.^[1]

That moat is meaningful but not broad. Patients and prescribers can switch among therapies, and larger pharmaceutical competitors have deeper commercial resources, so the company must keep proving clinical and commercial superiority to preserve its edge. The moat is probably widening modestly as the franchise gains scale, but it is still fragile because it depends so heavily on one asset.^[1]^[11]

Management & Leadership

Arcutis is not obviously founder-led from the public materials reviewed, and the CEO appears to be an externally appointed operator rather than a founder-entrepreneur. The recent operating record suggests management has executed well on commercialization, with the business showing continued revenue acceleration and a stronger operating profile in recent quarters.^[15]

Publicly available recent sources reviewed here do not provide a reliable current insider-ownership figure, so that should be treated as unavailable rather than inferred. The clearest capital-allocation signal is that management has prioritized commercial expansion and lifecycle development around ZORYVE instead of diversification through major acquisitions.^[8]^[15]^[20]

Key Risks

The biggest business risk is single-product concentration. Arcutis remains heavily dependent on ZORYVE, so any clinical setback, competitive erosion, or reimbursement disruption would affect the whole company rather than one small slice of the portfolio.^[1]^[11]

A second risk is competitive pressure in dermatology. The company operates in markets with established brands and well-funded rivals, so even a differentiated product can face formulary battles, promotional intensity, and slower-than-expected adoption as it expands into new indications.^[1]^[11]^[13]

A third risk is execution risk tied to growth. Arcutis has to scale sales, manage payer access, and support multiple label expansions while keeping operating discipline intact; that is a demanding balance for a company still relying on one commercial engine.^[15]^[20]

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of August 8, 2026 August 8, 2026